Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Fallopian Tube Neoplasms 2Vaccinia 1Solid Tumors 1Ovarian Neoplasms 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × taxane × Clear all
NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Fudan University

Phase 2 Recruiting
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Recruiting
100 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡